-
公开(公告)号:US20110150886A1
公开(公告)日:2011-06-23
申请号:US12988135
申请日:2009-04-17
申请人: Jill Caswell , Shane Olwill , James Johnston , Richard Buick , Thomas Jaquin , Declan Doherty , Christopher Scott
发明人: Jill Caswell , Shane Olwill , James Johnston , Richard Buick , Thomas Jaquin , Declan Doherty , Christopher Scott
IPC分类号: A61K39/395 , A61K31/7088 , A61P35/00 , C07K16/18 , C07H21/04
CPC分类号: C07K16/22 , A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K2317/31 , C07K2317/33 , C07K2317/73 , C07K2317/74 , A61K2300/00
摘要: Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis.
摘要翻译: 描述了对AREG和HBEGF具有结合特异性的交叉特异性抗体分子。 抗体分子可用于治疗癌症和与血管发生相关的疾病的方法。
-
公开(公告)号:US08846868B2
公开(公告)日:2014-09-30
申请号:US12988135
申请日:2009-04-17
申请人: Jill Caswell , Shane Olwill , James Johnston , Richard Buick , Thomas Jaquin , Declan Doherty , Christopher Scott
发明人: Jill Caswell , Shane Olwill , James Johnston , Richard Buick , Thomas Jaquin , Declan Doherty , Christopher Scott
CPC分类号: C07K16/22 , A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K2317/31 , C07K2317/33 , C07K2317/73 , C07K2317/74 , A61K2300/00
摘要: Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis.
摘要翻译: 描述了对AREG和HBEGF具有结合特异性的交叉特异性抗体分子。 抗体分子可用于治疗癌症和与血管发生相关的疾病的方法。
-
公开(公告)号:US20100111965A1
公开(公告)日:2010-05-06
申请号:US12445109
申请日:2007-10-11
申请人: James Johnston , Shane Olwill , Jill Brown , Nuala Morgan , Thomas Jaquin , Christopher Scott
发明人: James Johnston , Shane Olwill , Jill Brown , Nuala Morgan , Thomas Jaquin , Christopher Scott
IPC分类号: A61K39/395 , A61K31/7088 , C07K16/00 , A61P35/00 , C12Q1/68
CPC分类号: C12N15/1136 , A61K39/39558 , C07K16/22 , C07K2317/56 , C07K2317/73 , C12N2310/14 , C12N2320/31 , A61K2300/00
摘要: The invention provides a method of treating neoplastic disease in a subject, said method comprising the simultaneous, sequential or separate, administration to said subject of an effective amount of (i) an inhibitor of a first EGF, e.g. HB-EGF and (ii) an inhibitor of a second EGF, e.g. AREG. Also described are novel synergistic combinations of EGF inhibitors with topoisomerase inhibitors which attenuate tumour cell growth. Further described are novel anti AREG antibodies.
摘要翻译: 本发明提供一种治疗受试者的肿瘤疾病的方法,所述方法包括向所述受试者施用有效量的(i)第一EGF的抑制剂,例如, HB-EGF和(ii)第二EGF的抑制剂,例如。 AREG。 还描述了EGF抑制剂与拓扑异构酶抑制剂的新的协同组合,其减弱肿瘤细胞生长。 进一步描述的是新的抗AREG抗体。
-
公开(公告)号:US20100086551A1
公开(公告)日:2010-04-08
申请号:US12444928
申请日:2007-10-12
IPC分类号: A61K39/395 , C12N5/02 , A61K31/7088 , C07K16/00 , G01N33/53
CPC分类号: A61K31/7088 , A61K39/395 , A61K45/06 , A61K48/00 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K16/40 , C07K2317/73 , C07K2317/76 , C12N9/6472 , C12Q1/37 , G01N33/573 , G01N33/57496 , G01N2333/96466 , A61K2300/00
摘要: A method of inhibiting angiogenesis in a group of cells, a tissue or an organ includes administering an antibody molecule or nucleic acid encoding an antibody molecule to the cells, tissue or organ, wherein the antibody molecule specifically binds cathepsin S, but does not inhibit proteolytic activity of cathepsin S.
摘要翻译: 一种抑制一组细胞,组织或器官中的血管发生的方法包括将抗体分子或编码抗体分子的核酸施用于细胞,组织或器官,其中抗体分子特异性结合组织蛋白酶S,但不抑制蛋白水解 组织蛋白酶S的活性
-
公开(公告)号:US09321838B2
公开(公告)日:2016-04-26
申请号:US12296704
申请日:2007-04-10
申请人: Shane Olwill , Christopher Scott , Julie Gormley , Jaquin Thomas , Roberta Burden , Darragh McMeel , James Johnston
发明人: Shane Olwill , Christopher Scott , Julie Gormley , Jaquin Thomas , Roberta Burden , Darragh McMeel , James Johnston
IPC分类号: C07K16/00 , C07K16/28 , A61K31/00 , A61K39/395 , C07K16/40 , G01N33/574 , A61K39/00
CPC分类号: C07K16/28 , A61K31/00 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K16/40 , C07K2317/76 , G01N33/57492 , A61K2300/00
摘要: The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumor cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent.
摘要翻译: 本发明涉及一种抑制化学疗法诱导肿瘤细胞表面组织蛋白酶S上调的方法,该方法包括向所述细胞施用组织蛋白酶S抑制剂。 还提供了包含抗组织蛋白酶S抗体,特别是不抑制组织蛋白酶S的蛋白水解作用但仍然抑制血管生成并且包含组织蛋白酶S抑制剂和治疗剂的组合治疗的抗组织蛋白酶S抗体的治疗剂。
-
公开(公告)号:US20090269360A1
公开(公告)日:2009-10-29
申请号:US12296704
申请日:2007-04-10
申请人: Shane Olwill , Christopher Scott , Julie Gormley , Jaquin Thomas , Roberta Burden , Darragh McMeel , James Johnston
发明人: Shane Olwill , Christopher Scott , Julie Gormley , Jaquin Thomas , Roberta Burden , Darragh McMeel , James Johnston
IPC分类号: A61K39/395 , A61K33/24 , A61K31/435 , A61K31/495 , A61K31/7088 , C12N9/50 , C12N9/99 , C12N5/06 , G01N33/574
CPC分类号: C07K16/28 , A61K31/00 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K16/40 , C07K2317/76 , G01N33/57492 , A61K2300/00
摘要: The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumour cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent.
摘要翻译: 本发明涉及一种抑制化学疗法诱导肿瘤细胞表面组织蛋白酶S上调的方法,该方法包括向所述细胞施用组织蛋白酶S抑制剂。 还提供了包含抗组织蛋白酶S抗体,特别是不抑制组织蛋白酶S的蛋白水解作用但仍然抑制血管生成并且包含组织蛋白酶S抑制剂和治疗剂的组合治疗的抗组织蛋白酶S抗体的治疗剂。
-
公开(公告)号:US20120294946A1
公开(公告)日:2012-11-22
申请号:US13515884
申请日:2010-12-17
申请人: Christopher Scott , James Johnston , Shaun Spence , Danny McAuley , Francois Fay
发明人: Christopher Scott , James Johnston , Shaun Spence , Danny McAuley , Francois Fay
IPC分类号: A61K31/702 , A61P29/00 , A61P35/00 , A61P35/02 , A61P11/00 , A61P31/06 , A61P11/06 , A61P11/08 , A61P1/00 , A61P31/00 , A61P9/00 , A61P13/12 , A61P17/00 , A61P37/00 , A61P3/10 , A61P25/00 , A61K9/14 , B82Y5/00
CPC分类号: A61K47/48853 , A61K45/06 , A61K47/593 , A61K47/61 , A61K47/6921 , A61K47/6937 , A61K47/6939 , Y10S977/773 , Y10S977/906
摘要: There is provided a method for suppressing a pro-inflammatory immune response in a cell, comprising providing to a cell sialic acid or analogs thereof, wherein the sialic acid or analogs are presented by a substrate such that a pro-inflammatory immune response in a cell is suppressed or an anti-inflammatory immune response is increased in a cell. Further, there is provided a method of treatment of inflammatory disease in a subject in need thereof. There is also provided a drug delivery device and a biomaterial which can modulate the inflammatory response in a subject.
摘要翻译: 提供了一种抑制细胞中促炎免疫应答的方法,包括提供给唾液酸或其类似物的细胞,其中唾液酸或类似物由底物呈递,使得细胞中的促炎免疫应答 被抑制或抗细胞免疫应答增加。 此外,提供了在有需要的受试者中治疗炎症性疾病的方法。 还提供了可以调节受试者的炎症反应的药物递送装置和生物材料。
-
公开(公告)号:US08962032B2
公开(公告)日:2015-02-24
申请号:US13515884
申请日:2010-12-17
申请人: Christopher Scott , James Johnston , Shaun Spence , Danny McAuley , Francois Fay
发明人: Christopher Scott , James Johnston , Shaun Spence , Danny McAuley , Francois Fay
IPC分类号: A61P11/00 , A61P31/06 , A61P11/06 , A61P11/08 , A61P31/00 , A61P9/00 , A61P37/00 , A61P3/10 , A61P25/00 , A61K9/14 , A61K31/702 , A61K47/48 , A61K45/06
CPC分类号: A61K47/48853 , A61K45/06 , A61K47/593 , A61K47/61 , A61K47/6921 , A61K47/6937 , A61K47/6939 , Y10S977/773 , Y10S977/906
摘要: There is provided a method for suppressing a pro-inflammatory immune response in a cell, comprising providing to a cell sialic acid or analogs thereof, wherein the sialic acid or analogs are presented by a substrate such that a pro-inflammatory immune response in a cell is suppressed or an anti-inflammatory immune response is increased in a cell. Further, there is provided a method of treatment of inflammatory disease in a subject in need thereof. There is also provided a drug delivery device and a biomaterial which can modulate the inflammatory response in a subject.
摘要翻译: 提供了一种抑制细胞中促炎免疫应答的方法,包括提供给唾液酸或其类似物的细胞,其中唾液酸或类似物由底物呈递,使得细胞中的促炎免疫应答 被抑制或抗细胞免疫应答增加。 此外,提供了在有需要的受试者中治疗炎症性疾病的方法。 还提供了可以调节受试者的炎症反应的药物递送装置和生物材料。
-
9.
公开(公告)号:US20060168567A1
公开(公告)日:2006-07-27
申请号:US11040902
申请日:2005-01-21
申请人: Mark Kressin , Raymond Hornback , James Johnston , William Quinn
发明人: Mark Kressin , Raymond Hornback , James Johnston , William Quinn
IPC分类号: G06F9/44
CPC分类号: G06F9/44536
摘要: A method, system and apparatus for preserving platform independence of a program while supporting native accelerators for performance critical program objects. In a method for preserving platform independence of a program while supporting native accelerators for performance critical program objects, the method can include identifying a reference to a program object in a platform independent computer program and determining if a platform specific implementation of the program object has been separately stored in addition to a platform independent implementation of the program object. If it can be determined that a platform specific implementation of the program object has been separately stored in addition to a platform independent implementation of the program object, the platform specific implementation of the program object can be loaded in lieu of the platform independent implementation.
-
公开(公告)号:US20060163524A1
公开(公告)日:2006-07-27
申请号:US10533746
申请日:2003-10-31
申请人: Horst Lange , Christopher Roos , Roland Wagner , Martin Kropfgangs , Andrew Graydon , Richard Hartshorn , Jean-Pol Boutique , Patrick Delplanque , James Johnston
发明人: Horst Lange , Christopher Roos , Roland Wagner , Martin Kropfgangs , Andrew Graydon , Richard Hartshorn , Jean-Pol Boutique , Patrick Delplanque , James Johnston
IPC分类号: D06M15/643 , C08G77/26 , C08L83/00
CPC分类号: C11D3/3742 , A61K8/416 , A61K8/891 , A61K8/898 , A61Q5/00 , A61Q19/00 , C11D3/001 , C11D3/373 , D06M13/463 , D06M15/643 , D06M15/6436 , D06M2200/50 , D21H17/07 , D21H17/59 , D21H17/71 , D21H21/22 , D21H21/24 , Y10T442/2352 , Y10T442/2803
摘要: The invention relates to formulations containing at least one nitrogen-free polysiloxane compound, at least one polyamino polysiloxane and/or polyammonium polysiloxane compound, and/or at least one amino polysiloxane and/or ammonium polysiloxane compound, and an optional silicone-free cationic surfactant, a coacervate phase-forming agent, and carrier substances. Also disclosed are a method for the production of the inventive formulations and the use thereof for treating natural and synthetic fibrous materials.
-
-
-
-
-
-
-
-
-